Fluoroquinolone Resistance in Bacteroides fragilis following Sparfloxacin Exposure
暂无分享,去创建一个
[1] F. Yoshimura,et al. Active Efflux of Norfloxacin byBacteroides fragilis , 1998, Antimicrobial Agents and Chemotherapy.
[2] Jerome J. Schentag,et al. Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy , 1998, Antimicrobial Agents and Chemotherapy.
[3] D. Citron,et al. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections , 1997, Antimicrobial agents and chemotherapy.
[4] K. Bowker,et al. Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. , 1997, The Journal of antimicrobial chemotherapy.
[5] M. Jacobs,et al. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes. , 1997, The Journal of antimicrobial chemotherapy.
[6] R. Hill,et al. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium. , 1997, The Journal of antimicrobial chemotherapy.
[7] E. Goldstein. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] L. B. Hovde,et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model , 1996, Antimicrobial agents and chemotherapy.
[9] H. Neu,et al. In vitro activity of the new fluoroquinolone CP-99,219 , 1994, Antimicrobial Agents and Chemotherapy.
[10] M. Jacobs,et al. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes , 1994, Antimicrobial Agents and Chemotherapy.
[11] K. Aldridge. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria , 1994, Antimicrobial Agents and Chemotherapy.
[12] E. Perea,et al. Comparative activities of eight quinolones against members of the Bacteroides fragilis group , 1994, Antimicrobial Agents and Chemotherapy.
[13] J. Rotschafer,et al. Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system , 1993, Antimicrobial Agents and Chemotherapy.
[14] E. Goldstein. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] J. Rotschafer,et al. Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads , 1993, Antimicrobial Agents and Chemotherapy.
[16] R. Nichols,et al. Wound and intraabdominal infections: microbiological considerations and approaches to treatment. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] S. Schuldiner,et al. Mutants of the Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine. , 1993, The Journal of biological chemistry.
[18] E. Goldstein,et al. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria , 1992, Antimicrobial Agents and Chemotherapy.
[19] A. Neyfakh,et al. The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein , 1992, Antimicrobial Agents and Chemotherapy.
[20] V. Bidnenko,et al. Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[21] D. Hooper,et al. Mechanisms of action of and resistance to ciprofloxacin. , 1987, The American journal of medicine.
[22] M. Gellert,et al. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[23] I. Herrera. Theory of connectivity for formally symmetric operators. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[24] K. Bush,et al. Antimicrobial resistance in anaerobes. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] F. Goldstein,et al. Trends in bacterial resistance to fluoroquinolones. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] D. Citron,et al. Wadsworth Anaerobic Bacteriology Manual , 1980 .